The UK and US have signed a key bilateral deal that will preserve no duties on UK medicine products going into the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This commitment secures that tariffs on these key products will be held at nothing for a duration of three years.
This development is in response to recent warnings to significantly raise duties on branded pharmaceutical imports, with increases mentioned up to 100%.
"This arrangement between the UK strengthens the global environment for innovative medicines and introduces much-needed equity to transatlantic medicine commerce," an announcement said.
Commercial Impact
Drugs are one of the Britain's biggest exports to the US, which is by far the biggest buyer for large UK drugmakers.
Trade data show that in the year prior to the third quarter, the UK shipped drugs valued at over eleven billion pounds to the US. This value accounted for 17.4% of British export trade in that span.
"This deal safeguards work, increases capital expenditure and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary stated.
Key NHS Changes
The pact involves several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, rebates were more than twenty percent.
Broader Context
The deal comes amid a long-running row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that American patients were paying significantly more for the same drugs than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while substantial expansions have been pledged toward American operations.
A senior figure publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had declined as a share of its total funding over the previous ten-year period.
